Veru Inc VERU 深 滬
等待開盤 02-03 09:30:00 美东时间
2.57
+0.040
+1.58%
華盛通- 最 高2.80
- 今 開2.54
- 成交量 23.46万股
- 最 低 2.4749
- 昨 收 2.53
- 總市值 4124.93万
- 52周最高 7.40
- 市盈率 靜 --
- 換手率 1.46%
- 52周最低 2.10
- 委 比 -41.52%
- 總股本 1605.03万
- 歷史最高 245.70
- 量 比 3.15
- 振 幅 12.85%
- 歷史最低 2.14
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting
Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting Veru Inc. has announced that its Annual Meeting of Shareholders will be held on March 12, 2026, at its Miami location. During the meeting, shareholders will vote on the election of six members to the Board of Directors, who will serve
01-29 05:07
Veru Inc. Earnings Call: Lean Mass Wins, Losses Mount
Veru Inc (($VERU)) has held its Q4 earnings call. Read on for the main highligh...
2025-12-23 08:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25
Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $25.
2025-12-18 20:50
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Veru Inc. announced positive results from the Phase 2b QUALITY study of enobosarm in combination with GLP-1 RA, showing significant fat loss and lean mass preservation. The FDA has provided regulatory clarity, supporting incremental weight loss as a potential approval endpoint. Veru plans to initiate the Phase 2b PLATEAU study in Q1 2026, targeting older patients with obesity. Following the fiscal year end, the company completed a public offering...
2025-12-17 11:30
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Veru Inc., a late clinical stage biopharmaceutical company, announced multiple presentations at the 18th SCWD International Conference and Regulatory Workshop in Rome. Mitchell Steiner, Veru's Chairman, President & CEO, will present on weight loss drugs, novel strategies for sarcopenia and obesity, treatment approaches for muscle wasting, and regulatory considerations. Veru is developing enobosarm, a selective androgen receptor modulator, to enha...
2025-12-04 13:30
Veru to Present Two Abstracts at ObesityWeek 2025
Veru Inc. announced the presentation of two abstracts at ObesityWeek 2025 focusing on Enobosarm, a selective androgen receptor modulator, which aims to enhance fat loss while preserving lean mass in obese patients. The posters will discuss Enobosarm's effects in combination with GLP-1RA drugs, specifically its role in preventing fat regain and maintaining muscle mass after discontinuing semaglutide. Veru also plans a Phase 2b PLATEAU study to ass...
2025-10-31 12:30
Veru Announces Public Offering to Raise $23.4 Million
Veru ( ($VERU) ) has provided an update. On October 30, 2025, Veru Inc. entered...
2025-10-31 05:17
Veru Announces Pricing Of $25M Public Offering Of 1.4M Shares Of Common Stock At A Price Of $3.00 Per Unit
Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today the pricing of an
2025-10-30 20:08
